This opportunity funds research to develop and optimize cell-free protein synthesis (CFPS) platforms for discovery and production of biologicals such as antibody fragments, antigens, and enzymes. Projects should focus on scalable, flexible CFPS systems, including mammalian cell lysates, to enable streamlined manufacturing, decentralized production, and personalized medicines. The initiative supports advances leveraging synthetic biology and AI to improve efficiency, quality control, and accessibility of biopharmaceuticals.
Eligible applicants include legal entities established in EU and associated countries, with specific provisions allowing entities from the USA to receive funding. Eligibility conditions follow Horizon Europe Work Programme annexes, including financial and operational capacity requirements. Use of sa
